Ítems similars
-
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
per: Bekker, P, et al.
Publicat: (2007) -
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
per: Walters, M, et al.
Publicat: (2010) -
MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
per: Ungashe, S, et al.
Publicat: (2008) -
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
per: Satish Keshav, et al.
Publicat: (2013-01-01) -
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
per: Bekker, P, et al.
Publicat: (2009)